Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

De Novo Prostate Cancer: early-phase trial registry

1 of 1 indexed De Novo Prostate Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

De Novo Prostate Cancer: 1 US clinical trial tracked, 1 recruiting.

De Novo Prostate Cancer is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is VA Office of Research and Development, running 1 of these trials.

Enrollment posture brief

Registry condition de-novo-prostate-cancer

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

De Novo Prostate Cancer (this)De Novo Prostate Cancer (thi…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near De Novo Prostate Cancer

De Novo Prostate Cancer lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for De Novo Prostate Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. De Novo Prostate Cancer is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on De Novo Prostate Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

ADT + Nilutamide, Flutamide, & Bicalutamide Drug
1 trials
Goserelin, Histrelin, Leuprolide & Triptorelin Drug
1 trials
Salvage Local Therapy for locally recurrent disease Other
1 trials
PET-directed Local Therapy using Radiation Radiation
1 trials
PET-directed Local Therapy using Surgery Procedure
1 trials

US sites by state

Facility locations filed on De Novo Prostate Cancer trials. A trial with sites in several states counts in each.

Wisconsin 1 trials
Virginia 1 trials
Texas 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials
New Jersey 1 trials
North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this De Novo Prostate Cancer page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This De Novo Prostate Cancer condition card totals 1 registered trials; most-linked intervention ADT + Nilutamide, Flutamide, & Bicalutamide; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.